Shenghua L. Sun

Changsha, CN 
Changsha, CN 

Overview

Shenghua Sun practices practicing medicine in Changsha, China.

Their clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Eosinophilic Asthma, Pneumonia, and Asthma.

They are actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 2 clinical trials.

Locations

Changsha, China
Other Locations
Shanghai, 200062, China
China
Xiangya, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Salbutamol
Study Phase: Phase 3
View 1 Less Clinical Trial

49 Total Publications

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.
Journal: Cancer communications (London, England)
Published: November 29, 2025

Frequently Asked Questions about Shenghua L. Sun

Is Shenghua L. Sun a top-rated expert for Chronic Obstructive Pulmonary Disease (COPD)?

MediFind is an objective health platform that identifies experts based on real-world data. Shenghua L. Sun is classified as an Experienced expert for Chronic Obstructive Pulmonary Disease (COPD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Shenghua L. Sun participate in research or clinical trials?

Yes. Shenghua L. Sun has published 49 articles and abstracts on conditions like Chronic Obstructive Pulmonary Disease (COPD). You can view a list of Shenghua L. Sun's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sun's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile